NASDAQ: GRIGri Bio Inc Stock
$1.87-0.01 (-0.53%)
Updated Jun 22, 2026
GRI Price
$1.87
Fair Value Price
N/A
Market Cap
$3.31M
52 Week Low
$1.81
52 Week High
$80.36
P/E
-0.04x
P/B
0.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.91M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$12M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GRI Overview
GRI Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic agents within the United States. Its primary focus lies in addressing inflammatory, fibrotic, and autoimmune disorders. The company's leading drug candidate is GRI-0621, an oral inhibitor targeting type 1 Natural Killer T cells, which is currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for severe fibrotic lung conditions, including idiopathic pulmonary fibrosis. Beyond its flagship program, GRI Bio's pipeline also features GRI-0803, a novel oral agonist designed to activate type 2 Natural Killer T cells, currently in preclinical development for autoimmune diseases. Additionally, the company maintains a proprietary library exceeding 500 compounds and includes GRI-0124 and GRI-0729, both aimed at modulating inflammatory immune responses. Founded in 2009 and headquartered in La Jolla, California, GRI Bio, Inc. was previously known as Glycoregimmune, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GRI's potential to beat the market
- GRI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GRI
RankedUnranked of 467
RankedUnranked of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.92 | A | |
| $51.35 | A | |
| $2.16 | A |
Be the first to know about important GRI news, forecast changes, insider trades & much more!
GRI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GRI is good value based on its book value relative to its share price (0.31x), compared to the US Biotechnology industry average (5.1x)
P/B vs Industry Valuation
GRI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GRI due diligence checks available for Premium users.
Valuation
GRI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
15.1x
Market
7.94x
GRI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
5.1x
GRI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GRI's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
GRI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.3M
Liabilities
$794.0k
Debt to equity
0.08
GRI's short-term assets ($11.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRI's short-term assets ($11.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
$0.0
Financing
$6.5M
GRI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GRI vs Biotech Stocks
Gri Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.